Investor Opportunity: FDA Green-Light for NYSE Psychedelic Stock

Wall Street's hidden gems..................................................................... Greetings Investors, The buzz continues to rise over psychedelics. There has been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. [The U.S. psychedelics industry is growing with heavy private investment and even with the blessing of the chief U.S. drug-approval agency!]( It was last June that the U.S. Food and Drug Administration issued its first-ever draft [guidance on psychedelic drug clinical trials]( in key areas like psychedelic therapy and high-end herbal medicine, providing industry companies with a glimpse at a regulatory roadmap for drug development. In addition, the psychedelic drugs market is expected to grow from $4.9 billion in 2022 to $11.8 billion by 2029, says U.K.-based [Brandessence Market Research](. That's a compound annual growth rate of about 13.5%! Wall Street has some hidden gems hiding in this growing arena. This includes Cybin, Inc. which trades under the symbol “(NYSE:CYBN)” and is trading at pennies right now. Who is CYBN? (NYSE: CYBN) is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is revolutionizing mental healthcare and is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens. Can psychedelic drugs, once banned, help relieve mental illness? Many say yes. Decades after most hallucinogens were outlawed, researchers are now using them to treat disorders like PTSD, depression, and addiction. What is (NYSE:CYBN) doing? (NYSE: CYBN) is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Positive Data Released… (NYSE: CYBN) reported positive Phase 2 topline results for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder ("MDD"), demonstrating a 79% remission rate from depression - The company also announced positive topline results from Phase 1 studies of proprietary deuterated dimethyltryptamine ("dDMT") molecules CYB004 and SPL028, supporting clinical advancement and the successful development of an intramuscular ("IM") formulation. FDA Clearance! Wall Street is always on the lookout for FDA green lights in the biotech and biopharna space. (NYSE: CYBN) has received FDA clearance to initiate Phase 2a study of CYB004 in General Anxiety Disorder or GAD. The Company intends to initiate a Phase 2a study of CYB004 in the first quarter of 2024. The study will be a randomized, double-blind, active-controlled trial to assess the preliminary clinical efficacy, safety, tolerability, PK, and PD of CYB004 in participants with GAD. This trial will be conducted at study sites in the United States. New Patents! (NYSE: CYBN) has also strengthened its patent portfolio with the addition of 6 new patents in key jurisdictions. "During the past three months, we have continued to make exciting progress with positive topline data from our CYB003 and DMT programs," said Doug Drysdale, Chief Executive Officer of Cybin. "The data collected from our clinical trials forms the foundation of our next set of value-creating milestones, as we advance our key programs this year. For CYB003, the three-month Phase 2 efficacy data is expected in Q1 and will provide insights into the durability of treatment effect in MDD. Promising outcomes, such as a 79% remission from depression at 6 weeks in our Phase 2 CYB003 trial, and important safety and dosing findings in our Phase 1 dDMT studies, validate our path forward. Plans are underway to initiate a Phase 3 multisite trial of CYB003 for MDD, and with FDA clearance, we are progressing to a Phase 2a study of CYB004 for the treatment of GAD. We are proud of the rapid progress we have made and look forward to the important work ahead of us. We are encouraged by the positive findings across our clinical-stage programs to date and believe we are well on our way to providing more effective and patient-friendly treatment alternatives for a multitude of mental health disorders," concluded Drysdale. There’s a lot to look out for with (NYSE:CYBN) so keeping an eye on the company’s developments would be a smart strategy. You never know what news could be the driving catalyst to generate a potentially massive upside! In Summary… Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate (CAGR) of 16.3% over the next eight years, resulting in a whopping market value of $6.85 billion by 2027. The primary drivers of this growth are expected to be the rising incidence of depression and other mental health conditions in the United States, as well as a growing acceptance of psychedelic drugs as a viable treatment for depression. Clara Burtenshaw, who is a partner at Neo Kuma Ventures, the most significant venture capital fund in Europe that invests in psychedelic firms like Atai Life Sciences and Compass Pathways, [told]( CNBC on February 16, 2023: “Psychedelic healthcare is a very exciting area because it’s really this apex of drugs, clinics and experimental treatments.” Some of the primary players in the psychedelic market include giants like Johnson & Johnson (NYSE:[JNJ](20%26%20johnson/200406/)), Merck & Co., Inc. (NYSE:[MRK](20%26%20co%20inc/310158/)), and AbbVie Inc. (NYSE:[ABBV](20inc/1551152/)). Cybin, Inc. ([NYSE: CYBN]( is an emerging player in a rapidly growing arena that could see tremendous growth ahead and has some big developments going on! --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Cybin, Inc. (NYSE:CYBN) from Huge Alerts. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1700. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Cybin, Inc. (NYSE:CYBN) or Huge Alerts. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Cybin, Inc. (NYSE:CYBN) on Huge Alerts website for additional information about the relationship between Huge Alerts and SideWays Frequency. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com